Literature DB >> 9610690

The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.

K Taniguchi1, Y Yonemura, N Nojima, Y Hirono, S Fushida, T Fujimura, K Miwa, Y Endo, H Yamamoto, H Watanabe.   

Abstract

BACKGROUND: Hepatocyte growth factor receptor (c-met), autocrine motility factor receptor (AMFR), and urokinase-type plasminogen activator receptor (uPAR) are known to play important roles in tumor cell migration, invasion, and metastasis. The authors studied the relation between the expression patterns of these genes and the growth patterns of human gastric carcinoma.
METHODS: The relation between the expression of c-met, AMFR, and uPAR and clinicopathologic parameters was studied using immunohistochemical preparations from 102 paraffin embedded primary gastric carcinomas.
RESULTS: Of 102 cases, 43 (42%) had overexpression of c-met, and AMFR and uPAR immunoreactivity was observed in 41 cases (40%) and 38 cases (37%), respectively. Macroscopic examination revealed that all three genes were expressed in 1 (3%) of 32 early stage gastric carcinomas, 0 (0%) of 29 localized carcinomas (Borrmann types 1 and 2), and 16 (39%) of 41 infiltrating carcinomas (Borrmann types 3 and 4). In particular, the incidence (68%, 13 of 19 cases) of simultaneous expression of the three genes was significantly higher in Borrmann type 4 gastric carcinoma than in the other macroscopic types (P < 0.01). The overexpression of these genes was also closely associated with lymph node metastasis and peritoneal dissemination. In addition, the simultaneous overexpression of the three genes was associated with positive lymphatic vessel invasion and infiltrating type. Patients with tumors that simultaneously expressed all three genes had significantly poorer prognoses than those with tumors expressing only one or two of the genes. Furthermore, the number of genes expressed was closely related to the prognosis, and the Cox proportional hazards model identified this as one of the independent prognostic factors.
CONCLUSIONS: These results suggest that the expression patterns of c-met, AMFR, and uPAR may be closely associated with the progression and invasion of gastric carcinoma as well as the prognoses of the patients. Borrmann type 4 gastric carcinoma is characterized by the diverse and simultaneous expression of these three genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9610690

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

1.  Membrane-type 1 matrix metalloproteinase enhances lymph node metastasis of gastric cancer.

Authors:  Y Yonemura; Y Endo; T Takino; K Sakamoto; E Bandou; K Kinoshita; S Fushida; K Miwa; K Sugiyama; T Sasaki
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Antibody responses associated with the graft-versus-leukemia effect in adult T-cell leukemia.

Authors:  Masakatsu Hishizawa; Kazunori Imada; Tomomi Sakai; Momoko Nishikori; Nobuyoshi Arima; Mitsuru Tsudo; Takayuki Ishikawa; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

3.  Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Daniel V T Catenacci; Niall C Tebbutt; Irina Davidenko; André M Murad; Salah-Eddin Al-Batran; David H Ilson; Sergei Tjulandin; Evengy Gotovkin; Boguslawa Karaszewska; Igor Bondarenko; Mohamedtaki A Tejani; Anghel A Udrea; Mustapha Tehfe; Ferdinando De Vita; Cheryl Turkington; Rui Tang; Agnes Ang; Yilong Zhang; Tien Hoang; Roger Sidhu; David Cunningham
Journal:  Lancet Oncol       Date:  2017-09-25       Impact factor: 41.316

4.  Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.

Authors:  Nozomu Fuse; Yasutoshi Kuboki; Takeshi Kuwata; Tomohiro Nishina; Shigenori Kadowaki; Eiji Shinozaki; Nozomu Machida; Satoshi Yuki; Akira Ooki; Shinya Kajiura; Tetsuo Kimura; Takeharu Yamanaka; Kohei Shitara; Akiko Kawano Nagatsuma; Takayuki Yoshino; Atsushi Ochiai; Atsushi Ohtsu
Journal:  Gastric Cancer       Date:  2015-02-15       Impact factor: 7.370

5.  HGF-induced invasion by prostate tumor cells requires anterograde lysosome trafficking and activity of Na+-H+ exchangers.

Authors:  Joshua J Steffan; Brittany C Williams; Tomas Welbourne; James A Cardelli
Journal:  J Cell Sci       Date:  2010-03-09       Impact factor: 5.285

6.  Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma.

Authors:  Sang-Uk Han; Hwa-Young Lee; Jae-Ho Lee; Wook-Hwan Kim; Hyunja Nam; Hong Kim; Yong-Kwan Cho; Myung-Wook Kim; Kuhn Uk Lee
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

Review 7.  Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Authors:  Conor A Bradley; Manuel Salto-Tellez; Pierre Laurent-Puig; Alberto Bardelli; Christian Rolfo; Josep Tabernero; Hajrah A Khawaja; Mark Lawler; Patrick G Johnston; Sandra Van Schaeybroeck
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

8.  Elevated level of spindle checkprotein MAD2 correlates with cellular mitotic arrest, but not with aneuploidy and clinicopathological characteristics in gastric cancer.

Authors:  Chew-Wun Wu; Chin-Wen Chi; Tze-Sing Huang
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

Review 9.  Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.

Authors:  Y Zhang; S Doshi; M Zhu
Journal:  Br J Clin Pharmacol       Date:  2015-05-26       Impact factor: 4.335

10.  Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.

Authors:  Yu Sunakawa; Takeru Wakatsuki; Dongyun Yang; Wu Zhang; Yan Ning; Sebastian Stintzing; Stefan Stremitzer; Shinichi Yamauchi; Ana Sebio; Rita El-khoueiry; Syma Iqbal; Afsaneh Barzi; Armin Gerger; Michael Stotz; Mizutomo Azuma; Masahiko Watanabe; Wasaburo Koizumi; Heinz-Josef Lenz
Journal:  Pharmacogenet Genomics       Date:  2014-12       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.